Agri-Pharmaceutical Cancer Therapeutics

农业制药癌症治疗

• 批准号: 7058439
• 负责人: Donald M. Miller
• 金额: $ 44.64万
• 依托单位: UNIVERSITY OF LOUISVILLE
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-07-15 至 2007-07-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7058439
• 关键词: RNA binding protein; bioreactors; biotechnology; cell surface receptors; cervix neoplasms; combinatorial chemistry; dogs; drug design /synthesis /production; drug screening /evaluation; growth inhibitors; human papillomavirus; laboratory mouse; laboratory rabbit; neoplasm /cancer pharmacology; neoplasm /cancer vaccine; neutralizing antibody; nonhuman therapy evaluation; peptides; phosphoproteins; phosphopyruvate hydratase; plant genetics; protein binding; tobacco; vaccine development; viral vaccines

The development of modern genomics and proteomics has created an opportunity for the development of rational peptide-based cancer therapeutics. Using plant-biomass production systems, it is now possible to generate therapeutic peptides and proteins quite inexpensively and in large quantities. The overall goal of this proposal is to develop peptide-based cancer therapeutics which can be produced by plant biomass, particularly tobacco. In collaboration with Large Scale Biology, Inc., scientists at the James Graham Brown Cancer Center have developed the ability to express peptides and proteins in tobacco plants. The Large Scale Biology processing plant at Owensboro, Kentucky has the capability of GMP production of tobacco-based therapeutics. This proposal will take advantage of the Brown Cancer Center expertise in cancer drug and vaccine development and the Large Scale Biology expertise in plant molecular biology and expression technology to accomplish the following specific aims: 1. To identify growth inhibitory peptide aptamers targeted to nucleolin and alpha-enolase, two cellular proteins expressed on the surface of cancer cells. 2. To develop effective human papillomavirus vaccines that can be produced in tobacco. The unique and complementary experience of Dr. Miller in aptamer development and Dr. Jenson in vaccine creation will ensure the success of this project. The accomplishment of these goals will have the duel advantage for Kentucky of developing new compounds with therapeutic potential and generating revenue for farmers who participate in the program. The development of a viable agripharmaceutical industry in the state will have additional benefits. The experiments which are proposed in this grant will allow Brown Cancer Center scientists to translate their laboratory observations into early phase clinical trials.

现代基因组学和蛋白质组学的发展为开发合理的基于肽的癌症治疗剂创造了机会。使用植物生物质生产系统，现在可以非常便宜地大量生产治疗性肽和蛋白质。该提案的总体目标是开发基于肽的癌症治疗剂，其可以由植物生物质，特别是烟草产生。与大规模生物公司合作，詹姆斯·格雷厄姆·布朗癌症中心的科学家已经开发出在烟草植物中表达肽和蛋白质的能力。位于肯塔基州Owensboro的大型生物加工厂具有烟草治疗剂的GMP生产能力。该提案将利用布朗癌症中心在癌症药物和疫苗开发方面的专业知识以及大规模生物学在植物分子生物学和表达技术方面的专业知识，以实现以下具体目标： 1.为了鉴定靶向核仁素和α-烯醇化酶的生长抑制肽适体，核仁素和α-烯醇化酶是在癌细胞表面上表达的两种细胞蛋白。 2.开发有效的人乳头瘤病毒疫苗，可以在烟草中生产。 米勒博士在适体开发方面和詹森博士在疫苗创造方面的独特和互补经验将确保该项目的成功。这些目标的实现将为肯塔基州开发具有治疗潜力的新化合物和为参与该计划的农民创造收入带来双重优势。在该州发展可行的农业制药业将带来额外的好处。这项资助中提出的实验将允许布朗癌症中心的科学家将他们的实验室观察转化为早期临床试验。